EndoSphere's unique obesity solution makes the company a critical player in the diabetes/obesity space
San Francisco, CA (PRWEB) January 08, 2013
EndoSphere, Inc., a medical technology company focused on the non-invasive treatment of Metabolic Diseases including Obesity and Type 2 Diabetes, announced that CEO James T. McKinley is scheduled to present today at the 6th Annual OneMedForum conference. The January 7-9 conference is being held at the Sir Francis Drake Hotel in San Francisco.
The 6th Annual OneMedForum is featuring over 100 public and private emerging growth companies showcasing the most innovative technology in life sciences. Conference attendees include institutional investors, high net worth angel investors, family offices and business development executives throughout the US, Asia, and Europe who are developing and financing high growth medical technology, health care and life science companies.
The conference features companies from all sectors of life sciences and various levels of clinical development, seeking the establishment of a global presence. Special attention is paid to promising medical technologies, devices and diagnostics, complementing a strong presence of traditional biotech innovation. This year’s conference again features the China Forum, which has become a focal point for assembling many of China’s most influential and prominent investors and industry leaders in the healthcare industry to discuss opportunities for commercializing Western medical technologies in China’s rapidly growing healthcare market.
"OneMedPlace is excited to be hosting Jim McKinley and EndoSphere at our 6th Annual OneMedForum,” said OneMedPlace CEO Brett Johnson, “EndoSphere's unique obesity solution makes the company a critical player in the diabetes/obesity space."
“We are very pleased to have the opportunity to present EndoSphere’s new paradigm in obesity treatment,” said EndoSphere CEO James McKinley.
EndoSphere is a pioneer of endoscopically-insertable medical technologies for one of the world’s largest and fastest-growing categories of health issues: Metabolic Diseases including Obesity and Type 2 Diabetes. The company’s IP portfolio includes 29 issued and pending U.S. and international patents. EndoSphere’s flagship product, the SatiSphere™ System, was designed with insights from several of the world’s leading medical experts and clinical practitioners from the United States, Asia-Pacific, and Europe. Its patented technology provides a novel approach that combines the benefits of an incisionless, reversible, and repeatable solution.
The SatiSphere device treats obesity non-invasively by using the body’s natural physiology to regulate appetite and satiety. Clinical studies have shown that the SatiSphere device enables obese patients to achieve significant weight loss without the need for surgery or medication. In a pivotal randomized and controlled Phase II Clinical Trial conducted in Germany last year, patients treated with the SatiSphere device safely achieved four times greater Excess Weight Loss (EWL) than the diet-only Control Group. EndoSphere has received CE Mark regulatory approval for commercialization of the SatiSphere device in 31 countries.
“SatiSphere represents an exciting and major advance in the technology of devices to help combat obesity. It is simple to implant endoscopically, equally simple to remove, and has a novel mechanism of action at a hormonal level,” said EndoSphere Director John Lyon, “I believe that the SatiSphere device has the potential to be a valuable therapeutic choice for many more obese people worldwide than current conventional surgical options.”
FierceMedicalDevices named EndoSphere to its inaugural list of “the world’s top 15 most promising privately-held medical device companies”.
“EndoSphere’s exciting device, the Satisphere System, presents a non-surgical solution for the millions of people struggling to lose weight, demonstrating to be less invasive than bariatric surgery and more effective than diet and exercise,” said FierceMedicalDevices Editor Damian Garde.
Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that 35 percent of Americans are obese today. According to the World Health Organization (WHO), more than 1.4 billion people worldwide are overweight, and 500 million of them are clinically obese. According to Eric Schlosser, author of “Fast Food Nation”, annual healthcare costs in the US stemming from obesity and its co-morbidities are estimated at $240 billion.
Founded in 2006, EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies. The company has developed a novel approach to treating one of the world’s largest and fastest-growing categories of health issues: Metabolic Diseases including Obesity and Type 2 Diabetes. EndoSphere’s Intellectual Property portfolio includes 29 issued and pending U.S. and international patents. For more information, please visit http://www.EndoSphereInc.com.
Established in 2008, OneMedForum is the conference component of OneMedPlace, which provides an integrated media platform to showcase the best ideas and innovations in health and medicine globally. The media platform also includes: OneMedRadio, OneMedTV, OneMedSentinel, a global database of companies, and OneMedResearch, which tracks promising microcap public companies.